Renal toxicities of novel agents used for treatment of multiple myeloma

Rimda Wanchoo, Ala Abudayyeh, Mona Doshi, Amaka Edeani, Ilya G. Glezerman, Divya Monga, Mitchell Rosner, Kenar D. Jhaveri

Research output: Contribution to journalReview articlepeer-review

46 Scopus citations


Survival for patients with multiple myeloma has significantly improved in the last decade in large part due to the development of proteasome inhibitors and immunomodulatory drugs. These next generation agents with novel mechanisms of action as well as targeted therapies are being used both in the preclinical and clinical settings for patients with myeloma. These agents include monoclonal antibodies, deacetylase inhibitors, kinase inhibitors, agents affecting various signaling pathways, immune check point inhibitors, and other targeted therapies. In some cases, off target effects of these therapies can lead to unanticipated effects on the kidney that can range from electrolyte disorders to AKI. In this review, we discuss the nephrotoxicities of novel agents currently in practice as well as in development for the treatment of myeloma.

Original languageEnglish (US)
Pages (from-to)176-189
Number of pages14
JournalClinical Journal of the American Society of Nephrology
Issue number1
StatePublished - Jan 6 2017
Externally publishedYes

ASJC Scopus subject areas

  • Epidemiology
  • Critical Care and Intensive Care Medicine
  • Nephrology
  • Transplantation


Dive into the research topics of 'Renal toxicities of novel agents used for treatment of multiple myeloma'. Together they form a unique fingerprint.

Cite this